MTCYBP20

Across TCGA pan-cancer cohorts, MTCYBP20 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated MTCYBP20 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MTCYBP20 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTCYBP20 expression acts as an unfavorable survival marker, although some lineages such as KIRC show a favorable association.

STAD, UVM, and READ are the cancer types where MTCYBP20 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	All	0.519	0.689	<.001	141	view →
UVM	OS	Tertile	All	0.037	0.858	<.001	108	view →
READ	OS	Tertile	II,III,IV	0.083	0.919	<.001	36	view →
LGG	DFS	Tertile	All	0.509	0.748	<.001	27	view →
KIRC	DFS	Tertile	III,IV	0.801	0.616	.031	21	view →
DLBC	OS	Tertile	All	0.526	0.936	.002	18	view →
COAD	OS	Tertile	III,IV	0.282	0.704	.038	18	view →
LUAD	OS	Tertile	IV	0.114	0.560	.038	18	view →
GBM	OS	Tertile	All	0.086	0.415	.010	9	view →
ACC	DFS	Tertile	III,IV	0.058	0.379	.027	9	view →
SKCM	OS	Tertile	All	0.077	0.392	.019	6	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

MTCYBP20–STAD (DFS)

Open the STAD breakdown →